Elisa K Boden1,2, James B Canavan3,4,5, Christopher J Moran6,7, Katelyn McCann4, William A Dunn4,5, Francis A Farraye8, Ashwin N Ananthakrishnan5,7, Vijay Yajnik5,7, Roopali Gandhi5,9, Deanna D Nguyen5,7, Atul K Bhan10,11, Howard L Weiner5,9, Joshua R Korzenik3,5, Scott B Snapper3,4,5. 1. Division of Gastroenterology, Virginia Mason Medical Center, Seattle, WA. 2. Benaroya Research Institute, Seattle, WA. 3. Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, MA. 4. Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA. 5. Department of Medicine, Harvard Medical School, Boston, MA. 6. Division of Pediatric Gastroenterology, MassGeneral Hospital for Children, Boston, MA. 7. Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA. 8. Section of Gastroenterology, Boston Medical Center, Boston University School of Medicine, Boston, MA. 9. Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Boston, MA. 10. Department of Pathology, Massachusetts General Hospital, Boston, MA. 11. Department of Pathology, Harvard Medical School, Boston, MA.
Abstract
AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. RESULTS: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. CONCLUSION: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.
AIM: The aim of this study was to determine the immunologic effects and safety of oral anti-CD3 in patients with ulcerative colitis (UC). METHODS: An open-label pilot study of orally delivered anti-CD3 was performed in patients with moderate-to-severe UC. The primary end points were changes in immunologic parameters and evaluation for safety. RESULTS: Six subjects received oral OKT3. Biologic effects of oral anti-CD3 included significantly increased proliferation in response to anti-CD3 and anti-inflammatory gene expression profile in peripheral blood mononuclear cells. No serious treatment-related adverse events occurred. CONCLUSION: Orally delivered anti-CD3 resulted in immunologic changes in patients with UC.
Entities:
Keywords:
muromonab-CD3; regulatory T cells; ulcerative colitis
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre S Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner Journal: Nat Med Date: 2006-05-21 Impact factor: 53.440
Authors: James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg Journal: Inflamm Bowel Dis Date: 2008-12 Impact factor: 5.325
Authors: Yaron Ilan; Ehud Zigmond; Gadi Lalazar; Adi Dembinsky; Ami Ben Ya'acov; Nila Hemed; Ibrahim Kasis; Elizabeth Axelrod; Lidya Zolotarov; Athalia Klein; Madi El Haj; Roopali Gandhi; Claire Baecher-Allan; Henry Wu; Gopal Murugaiyan; Pia Kivisakk; Mauricio F Farez; Francisco J Quintana; Samia J Khoury; Howard L Weiner Journal: J Clin Immunol Date: 2009-09-16 Impact factor: 8.317
Authors: Piotr Eder; Aleksandra Zielińska; Jacek Karczewski; Agnieszka Dobrowolska; Ryszard Słomski; Eliana B Souto Journal: J Nanobiotechnology Date: 2021-10-29 Impact factor: 10.435